25 reports

  • 3.3 GLOBAL AND HISTORICAL TRENDS
  • MM, 12-Month Total Prevalence of PTSD (%), Men and Women, Ages ≥18 Years, 2018

An exploratory study in the WHO World Mental Health Surveys', World Psychiatry, ##, pp. ##-##.

  • Anxiety Disorder
  • Japan
  • United States
  • World
  • Forecast
  • MM, Sources Used and Not Used to Forecast the 12-Month Total Prevalent Cases of
  • MM, 12-Month Total Prevalence of PTSD (%), Men and Women, Ages ≥18 Years, 2018

ONE, ##(##), p. e##.

  • Anxiety Disorder
  • Therapy
  • United States
  • World
  • Forecast
  • MARKET OPPORTUNITY BY PRODUCT
  • MARKET SIZING 2017

The one-month prevalence of PTSD is between ##% and ##% in Germany.

  • Anxiety Disorder
  • Eli Lilly & Co Ltd
  • GlaxoSmithKline plc
  • Lundbeck Inc.
  • Pfizer Inc.

You can easily book an appointment with one online.

  • Anxiety Disorder
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Clinical Trial profile. 55 Trial Title
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Anxiety Disorder
  • Clinical Trial
  • World
  • Product Initiative
  • Pfizer Inc.
  • Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Product Development Milestones

Patients will be randomized to receive one of two doses of BNC## (##mg or 2000mg) or one of two controls, placebo or ##. ##mg Lorazepam.

  • Anxiety Disorder
  • Psychotic Disorder
  • United States
  • Product Initiative
  • Bionomics
  • 07.1 UNDERSTANDING THE DISORDER
  • 07.5 MANAGEMENT

PTSD is a mental health condition and is usually observed in individuals who have undergone a traumatic experience.

  • Anxiety Disorder
  • Azevan Pharmaceuticals, Inc.
  • GlaxoSmithKline plc
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Product Development Milestones
  • Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Product Development Milestones

Patients will be randomized to receive one of two doses of BNC## (##mg or 2000mg) or one of two controls, placebo or ##. ##mg Lorazepam.

  • Anxiety Disorder
  • Therapy
  • United States
  • Product Initiative
  • Bionomics
  • Clinical Trial profile. 100 Trial Title
  • Target

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Anxiety Disorder
  • Clinical Trial
  • Pharmaceutical
  • World
  • Product Initiative
  • Target
  • Clinical Trial profile. 27 Trial Title

The prominent features of this report are - ##.

  • Anxiety Disorder
  • Hormone
  • World
  • Product Initiative
  • Pfizer Inc.
  • Clinical Trial profile. 46 Trial Title
  • Clinical Trial profile. 29 Trial Title

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Anxiety Disorder
  • Mental Health
  • World
  • Product Initiative
  • GlaxoSmithKline plc
  • SRX-246 - DRUG PROFILE
  • ZL-006 - DRUG PROFILE

Post-traumatic stress disorder (PTSD) is a mental health condition that' s triggered by a terrifying event either experiencing it or witnessing it.

  • Anxiety Disorder
  • United States
  • Company
  • Product Initiative
  • Tonix Pharmaceuticals Holding Corp.
  • Target
  • Clinical Trial profile. 81 Trial Title

The prominent features of this report are - ##.

  • Anxiety Disorder
  • Pharmaceutical
  • World
  • Product Initiative
  • Pfizer Inc.
  • Target
  • Target

Juruena, MD, MPhil, Dip CBT, MSc, PhD. and Edgar Jones, PhD, DPhil, also from The Institute of Psychiatry, Psychology and Neuroscience (IoPPN) at King' s College London which is one of the world' s leading postgraduate teaching and research centres in mental health sciences

  • Anxiety Disorder
  • Clinical Trial
  • World
  • Product Initiative
  • Tonix Pharmaceuticals Holding Corp.

Besins Healthcare SA Bayer AG ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Barij Essence Pharmaceutical Company Source: GlobalData' s Pharma Intelligence Center Clinical Trials Database (*)Trials are taken for a time period of 1995

  • Anxiety Disorder
  • Therapy
  • World
  • Product Initiative
  • Pfizer Inc.

Joseph' s deliver optimal mental health solutions to their patients and partner with them in this initiative that will address a growing challenge in treating mental health patients, " said Joe Perekupka, vice president at BrainsWay.

  • Anxiety Disorder
  • United States
  • Company
  • Product Initiative
  • Brainsway Ltd.
  • 05. Introduction

Globally, October ## is celebrated as ' World Mental Health Day' to increase awareness regarding mental health and support initiatives to improve mental health.

  • Anxiety Disorder
  • World
  • Eli Lilly & Co.
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Nov 07, 2017: Tonix Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Programs Update
  • Apr 17, 2017: Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Programs Update

Each unit consists of one share of common stock, one class A warrant to purchase one share of common stock, and one class B warrant to purchase one share of common stock.

  • Anxiety Disorder
  • Pharmaceutical
  • United States
  • Corporate Finance
  • Tonix Pharmaceuticals Holding Corp.
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Anxiety Disorder
  • Neurology
  • Therapy
  • World
  • Product Initiative
  • SRX-246 - DRUG PROFILE
  • R&D Progress

Post-traumatic stress disorder (PTSD) is a mental health condition that' s triggered by a terrifying event either experiencing it or witnessing it.

  • Anxiety Disorder
  • Therapy
  • United States
  • Product Initiative
  • Tonix Pharmaceuticals Holding Corp.
  • Target
  • Clinical Trial Profile Snapshots

The prominent features of this report are - ##.

  • Anxiety Disorder
  • Hormone
  • World
  • Product Initiative
  • Torrent
  • Introduction
  • Executive Summary

PTSD IS A MENTAL HEALTH CONDITION THAT IS TRIGGERED BY EITHER EXPERIENCING OR WITNESSING A TRAUMATIC EVENT.

  • Anxiety Disorder
  • Depression
  • Company
  • Product Initiative
  • Otsuka Pharmaceutical Co., Ltd.
  • Clinical Trial profile. 165 Trial Title
  • Target

The prominent features of this report are - ##.

  • Anxiety Disorder
  • Clinical Trial
  • Therapy
  • World
  • Product Initiative
  • R&D Progress Research and Development Brief
  • AVN-628 - DRUG PROFILE

CAPS-## raters were certified MA-level or above in mental health fields who underwent a rigorous training and certification process.

  • Anxiety Disorder
  • Pharmaceutical
  • United States
  • Company
  • Product Initiative
  • SRX-246 - DRUG PROFILE
  • D-473 - DRUG PROFILE

IN THIS TRIAL, OVER ## PATIENTS WILL BE RANDOMIZED TO RECEIVE ONE OF FOUR TREATMENTS ## MG ITI-##, ## MG ITI-##, ## MG RISPERIDONE (ACTIVE CONTROL) OR PLACEBO IN A ##:##:##:## RATIO.

  • Anxiety Disorder
  • Pharmaceutical
  • Research And Development
  • United States
  • Company Operations